Helen Torley joins Onyx Pharmaceuticals
Takes the position of executive vp and chief commercial officer
Torley reports to Anthony Coles, president and chief executive officer, and take responsibility for all commercial activities related to Nexavar and the potential launch of carfilzomib, the development of the company's European commercial organisation, and initiatives to grow business and capabilities in the US and Europe.
Before joining Onyx, Torley spent nine years at Amgen where she most recently served as vice president and general manager of the Bone Health Business Unit, after leading the company's Nephrology Business Unit for five years.
From 1997 to 2002, she held various senior management positions at Bristol Myers Squibb.
Torley began her industry career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, overseeing phase IIIb and IV clinical studies across all therapeutic areas, including oncology.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact
With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities
The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258
The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists